Under the conditions of the agreement.

Bristol-Myers Squibb plans to preserve Amira Pharmaceuticals’ scientists who work on both of these programs and they’ll remain located in NORTH PARK. ‘As part of the continuing execution of our focused BioPharma technique, Bristol-Myers Squibb has recognized fibrotic diseases as a location of high unmet medical want that complements our research efforts in several of our therapeutic areas,’ stated Elliott Sigal, executive vice president, chief scientific president and officer, Research and Development, Bristol-Myers Squibb.Women with high-grade abnormalities should always be treated to prevent cervical cancer. However, doctors should give consideration to treatment of youthful women with low-quality disease because many of these instances will regress back again to regular without therapy. Most ladies with low-grade disease ought to be closely observed with no treatment, unless their condition progresses. This management strategy will reduce the chance of subsequent preterm delivery likely. Additional authors of the report include Lynn Sadler, Melissa Exeter and Lesley McCowan, M.D., in Department of Gynaecology and Obstetrics at the University of Auckland, New Zealand; Wenquan Wang in Division of Biostatistics at the UI; and John Whittaker of the National Women’s Hospital in Auckland, New Zealand.

Related Articles

Other Articles from "doctor":